Advancing Cell Therapeutics
Tacitus Therapeutics is a clinical-stage biotechnology company developing advanced medicines for treatment of blood cancers, immune disorders, and other intractable disease conditions. Our mission is to pioneer best-in-class therapies using proprietary cell expansion, differentiation, and engineering platform technologies that overcome the limitations of traditional cell transplantation. Initial targets include a lead clinical program (HSC100) investigating the treatment of blood cancers, followed by preclinical programs to address clotting disorders and other serious unmet medical needs.
Tacitus Therapeutics’ guiding principle is to focus development efforts on next-gen stem cell therapies that offer curative potential, a clear underlying mechanism of action, and potential for future improvements. To achieve this we bring together leading experts and partnered institutions alongside our platform technology for stem cell expansion, differentiation, and engineering.